SCHEMBL3436342

SCHEMBL3436342

Cc1cc(C(=O)O)ccc1N1CCC(C(N)=O)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
POLB P06746 4/20 0.56
KDM4E B2RXH2 4/20 0.56
HSD17B10 Q99714 3/20 0.56
GAA P10253 3/20 0.56
NR4A1 P22736 1/20 0.56
MYC P01106 1/20 0.54
ESR1 P03372 1/20 0.54
ALOX15 P16050 1/20 0.54
PTPN7 P35236 1/20 0.54
TDP1 Q9NUW8 3/20 0.48
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3436340 0.90 POLB (0.64) ALDH1A1POLBKDM4EHSD17B10GAA
SCHEMBL3436339 0.85 ALDH1A1 (0.58) ALDH1A1POLBKDM4EHSD17B10ALOX15
SCHEMBL12800749 0.84 ALDH1A1 (0.62) ALDH1A1POLBKDM4EHSD17B10GAA
SCHEMBL1664707 0.84 HSD17B10 (0.56) ALDH1A1POLBKDM4EHSD17B10GAA
SCHEMBL29113608 0.81 GAA (0.64) ALDH1A1POLBKDM4EHSD17B10GAA
SCHEMBL30683883 0.81 GAA (0.64) ALDH1A1POLBKDM4EHSD17B10GAA
SCHEMBL3436347 0.80 ALDH1A1 (0.45) ALDH1A1POLBKDM4EGAATDP1
SCHEMBL3554546 0.80 KDM4E (0.51) ALDH1A1POLBKDM4EHSD17B10GAA
SCHEMBL3436341 0.80 HSD17B10 (0.51) ALDH1A1POLBKDM4EHSD17B10GAA
SCHEMBL2557677 0.80 ALDH1A1 (0.62) ALDH1A1POLBKDM4EGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
EP-2009005-A1 AZOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 ALDH1A1 975/4885POLB 4512/4885KDM4E 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.